@inproceedings{inproceedings, title  = {{Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation (non-transplant consolidation NTC) therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: Results from the Myeloma X (Intensive) Trial}},

 url = {{}},

 year = {{2016}},

 month = {{4}},

 author = {{Ashcroft AJ and Cairns DA and Williams C and Hockaday A and Cavanagh JD and Snowden JA and Parrish C and Yong K and Cavet J and Hunter H and Bird JH et al}},

 volume = {{173}},

 journal = {{BRITISH JOURNAL OF HAEMATOLOGY}},

 pages = {{165-165}},

 note = {{Accessed on 2024/12/28}}}